In our online shop you can buy and you do not need a prescription. Also you will find a description of products, detailed price and will be able to get qualified advice. Then you can see the drug Tamiflu.
The drug Tamiflu - against influenza and its complications.
Recent studies have shown that the drug Tamiflu (oseltamivir), manufacturer - F.Hoffmann-La Roche, significantly reduces the probability of complications arising from influenza, and consequently, death of disease.
Each year the influenza virus infects every tenth adult human being and every third child. Epidemics of influenza usually occur seasonally - in the autumn and winter months (October to April). Moreover, every 10-40 years is the threat of an influenza pandemic, when a new strain of virus against which humanity has no immunity, resulting in simultaneous outbreaks of influenza throughout the world and causes huge numbers of deaths. According to the World Health Organization, today, the probability of occurrence of an influenza pandemic is very high.
Unlike many acute viral infections, influenza is especially dangerous because it can cause complications such as bronchitis, sinusitis, middle ear otitis, pneumonia, and myocardial infarction and encephalitis, and lead to hospitalization and even death.
New research on the drug Tamiflu complements the existing results of clinical studies, where Tamiflu has shown a decrease of secondary complications by 67% and the real benefits of the drug in everyday clinical practice.
A study conducted by a major American company, was devoted to the study of cases of pneumonia and heart attacks (myocardial infarction) within one month after diagnosis «flu» patients, some of which do not take medicine, and the remaining were discharged drug Tamiflu. Patients taking the drug Tamiflu, said it was reducing the risk of pneumonia and heart attacks compared with patients not to take medicine.
Another study showed that the drug Tamiflu treatment of hospitalized patients with influenza significantly reduces the likelihood of fatal outcome in patients who started treatment within three days after the first symptoms.
The drug Tamiflu is active against all influenza viruses. Its operation is based on blocking enzyme action neuraminidase on the surface of the virus. When Neuraminidase inhibited, the virus can no longer be in cages, carriers, and die. Thus, the virus is not able to spread further and infect other cells of the body. Unlike other antiviral agents, inhibitors Neuraminidase effective against both types of influenza - virus A and B.
Tamiflu has proven its clinical efficacy in the treatment of influenza in adults and children over 1 year and for the prevention of influenza in adults and adolescents over 13 years.
When using Tamiflu it has been noted that:
* Reducing the severity of symptoms by 38%;
* Reducing the secondary complications, including bronchitis, pneumonia and sinusitis - 67%;
* Reducing the duration of influenza illness - 37%.
In children the use of the drug Tamiflu reduces the severity and duration of flu symptoms by 26%, and compared with standard drugs, the incidence of otitis middle ear - to 44%.
The benefits of Tamiflu is not limited to easing the symptoms of influenza. Objective data show that the drug Tamiflu treatment leads to a reduction in the number of secondary diseases of the respiratory tract, bronchitis, pneumonia and hospital admissions. New data show that taking Tamiflu reduces the risk of complications from the flu and the likelihood of a fatal outcome.
During clinical trials the drug Tamiflu has demonstrated high efficiency, good portability of the body and greater security.
The drug Tamiflu, WHO has been tested against different strains of influenza, and demonstrated its effectiveness against strains H7 and H9 avian influenza virus. Recent data also demonstrated the effectiveness of Tamiflu against bird flu strain H5N1, which is now distributed in South-East Asia.
WHO recommendations state that the stockpiling of antiviral drugs to date is the only way to ensure the availability of adequate quantities of drugs in the event of a pandemic. In the past few months, Roche has worked with many governments, to discuss their needs in stocks Tamiflu, and has received and fulfilled orders from around 40 countries. The size of these orders varies from country to country. For example, France, Finland, Iceland, Ireland, Luxembourg, Netherlands, New Zealand, Norway, Switzerland and United Kingdom are already doing or planning to do the necessary stocks of Tamiflu, a medicine to ensure 20-40% of its population.
